Browse > Article
http://dx.doi.org/10.24304/kjcp.2018.28.3.174

Drug Use Evaluation of Clostridium difficile Infection in Elderly Patients and Risk Factors of Non-improving Group  

Noh, Hyun Jeong (Graduate School of Converging Clinical & Public Health, Ewha Womans University)
Ham, Jung Yeon (Department of Pharmacy, Kangbuk Samsung Medical Center)
Lee, Ja Gyun (Department of Pharmacy, Kangbuk Samsung Medical Center)
Rhie, Sandy Jeong (Graduate School of Converging Clinical & Public Health, Ewha Womans University)
Publication Information
Korean Journal of Clinical Pharmacy / v.28, no.3, 2018 , pp. 174-180 More about this Journal
Abstract
Objective: Clostridium difficile Infection (CDI) is one of the common nosocomial infections. As elderly population increases, the proper treatment has been emphasized. We investigated the risk factors associated with CDI unimprovement in elderly patients. Furthermore, we performed drug use evaluation of old CDI patients and oldest-old CDI patients. Methods: It was a retrospective study using electronic medical record at Kangbuk Samsung Medical Center (KBSMC) from January 2016 to December 2017. Seventy three patients aged 65 years or older, diagnosed with CDI by Clostridium difficile Toxin B Gene [Xpert] were screened and they were assessed for risk factors regarding unimprovement status. We also evaluated drug use evaluation in old patients ($65{\leq}age$<80) and oldest-old patients ($80{\leq}age$) by assessing the use of initial therapy, severity, dose, route, treatment course, days of use, total days of use and treatment outcome of initial therapy. Results: Out of 73 patients aged over 65 years, four patients were excluded because they did not receive any treatment. There were 31 improved patients and 38 unimproved patients after initial therapy. We were able to find out patients with surgical comorbidity or endocrine comorbidity (especially, diabetes mellitus) had 2.885 more risk of becoming unimproved than those patients without surgical comorbidity or endocrine comorbidity. Drug use evaluation for CDI was generally fair, but vancomycin as initial therapy is more recommended than metronidazole. Conclusion: Although age, antibiotics exposure, use of antacids are all important risk factors for CDI, our result did not show statistical significance for these risk factors. However, the study is meaningful because the number of elderly population keeps increasing and recently updated guideline suggests the use of vancomycin as drug of choice for CDI.
Keywords
Clostridium difficile; elderly; drug use; Clostridium difficile infection;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kelly CP, LaMont JT. Clostridium difficile: more difficult than ever. N Engl J Med 2008;359:1932-40.   DOI
2 Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control HospEpidemiol 2010;31(5):431-55.
3 Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficileassociated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45(3):302-7.   DOI
4 Foster NF, Collins DA, Ditchburn SL, et al. Epidemiology of Clostridium difficile infection in two tertiary-care hospitals in Perth, Western Australia: a cross-sectional study. New Microbes New Infect 2014;3:64-71.
5 Kim HH, Kim YS, Han DS, et al. Clinical differences in Clostridium difficile infection based on age: A multicenter study. Scand J of Infect Dis 2014;46:46-51.   DOI
6 Chopra T, Goldstein EJ. Clostridium difficile Infection in Long-term Care Facilities: A Call to Action for Antimicrobial Stewardship. Clin Infect Dis 2015;Vol 60:S72-6.   DOI
7 Kim JH, Toy D, Muder RR. Clostridium difficile infection in a long-term care facility: hospital-associated illness compared with long-term care-associated illness. Infect Control Hosp Epidemiol 2011;32:656- 60.   DOI
8 Cambell RJ, Giljahn L, Machesky K, et al. Clostridium difficile infection in Ohio hospitals and nursing homes during 2006. Infect Control Hosp Epidemiol 2009;30:526-33.   DOI
9 Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999;26:259-65.   DOI
10 Olanipekun TO, Salemi JL, Mejia de Grubb MC, et al. Clostridium difficile infection in patients hospitalized with type 2 diabetes mellitus and its impact on morbidity, mortality, and the costs of inpatient care. Diabetes Res Clin Pract 2015;116:68-79.
11 Collier A, McLaren J, Godwin J, et al. Is Clostridium difficile associated with the '4C'antibiotics? A retrospective observational study in diabetic foot ulcer patients. Int J Clin Pract 2014;Vol 68(5):628-32.   DOI
12 King RN, Lager SL. Incidence of Clostridium difficile Infections in patients receiving antimicrobial and acid-suppression therapy. Pharmacotherapy 2011;7:642-48.
13 McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204-10.   DOI
14 McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66(7):987-94.   DOI
15 Korean Statistical Information Service, Population in Numbers of America. Available from http://kosis.kr/visual/populationKorea/PopulationByNumber/PopulationByNumberMain.do?mb=N&menuId=M_1_4& themaId=D03. Accessed June 18, 2018.
16 Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62.   DOI